Liquidia Technologies Inc
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The comp… Read more
Liquidia Technologies Inc (LQDA) - Net Assets
Latest net assets as of September 2025: $22.05 Million USD
Based on the latest financial reports, Liquidia Technologies Inc (LQDA) has net assets worth $22.05 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($275.98 Million) and total liabilities ($253.93 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $22.05 Million |
| % of Total Assets | 7.99% |
| Annual Growth Rate | N/A |
| 5-Year Change | 8.71% |
| 10-Year Change | N/A |
| Growth Volatility | 52.9 |
Liquidia Technologies Inc - Net Assets Trend (2016–2024)
This chart illustrates how Liquidia Technologies Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Liquidia Technologies Inc (2016–2024)
The table below shows the annual net assets of Liquidia Technologies Inc from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $77.28 Million | +63.40% |
| 2023-12-31 | $47.29 Million | -47.70% |
| 2022-12-31 | $90.42 Million | +38.55% |
| 2021-12-31 | $65.27 Million | -8.19% |
| 2020-12-31 | $71.09 Million | +103.41% |
| 2019-12-31 | $34.95 Million | +87.01% |
| 2018-12-31 | $18.69 Million | +155.47% |
| 2017-12-31 | $-33.69 Million | -84.66% |
| 2016-12-31 | $-18.25 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Liquidia Technologies Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 47523292900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $85.00K | 0.11% |
| Other Components | $636.68 Million | 823.92% |
| Total Equity | $77.28 Million | 100.00% |
Liquidia Technologies Inc Competitors by Market Cap
The table below lists competitors of Liquidia Technologies Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ashland Global Holdings Inc
NYSE:ASH
|
$2.15 Billion |
|
CECEP Solar Energy Co Ltd
SHE:000591
|
$2.15 Billion |
|
FREEDOM HLDG DL-001
F:DMW2
|
$2.15 Billion |
|
Taihan Electric Wire Co Ltd
KO:001440
|
$2.16 Billion |
|
Genscript Biotech Corporation
PINK:GNNSF
|
$2.15 Billion |
|
Codan Ltd
AU:CDA
|
$2.15 Billion |
|
SWCC SHOWA HLDGS CO. LTD.
F:7VY
|
$2.15 Billion |
|
SWECO AB B SK 1-
F:7W71
|
$2.15 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Liquidia Technologies Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 47,293,000 to 77,275,000, a change of 29,982,000 (63.4%).
- Net loss of 130,394,000 reduced equity.
- New share issuances of 138,551,000 increased equity.
- Other factors increased equity by 21,825,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-130.39 Million | -168.74% |
| Share Issuances | $138.55 Million | +179.3% |
| Other Changes | $21.82 Million | +28.24% |
| Total Change | $- | 63.40% |
Book Value vs Market Value Analysis
This analysis compares Liquidia Technologies Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 36.36x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $-3.59 | $35.70 | x |
| 2017-12-31 | $-3.92 | $35.70 | x |
| 2018-12-31 | $2.61 | $35.70 | x |
| 2019-12-31 | $1.89 | $35.70 | x |
| 2020-12-31 | $2.10 | $35.70 | x |
| 2021-12-31 | $1.31 | $35.70 | x |
| 2022-12-31 | $1.48 | $35.70 | x |
| 2023-12-31 | $0.73 | $35.70 | x |
| 2024-12-31 | $0.98 | $35.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Liquidia Technologies Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -168.74%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -931.65%
- • Asset Turnover: 0.06x
- • Equity Multiplier: 2.98x
- Recent ROE (-168.74%) is below the historical average (-104.18%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | -120.56% | 1.56x | 0.00x | $-14.11 Million |
| 2017 | 0.00% | -401.68% | 0.49x | 0.00x | $-25.79 Million |
| 2018 | -284.34% | -1962.92% | 0.05x | 2.64x | $-55.00 Million |
| 2019 | -136.16% | -589.48% | 0.12x | 1.97x | $-51.08 Million |
| 2020 | -84.07% | -8080.11% | 0.01x | 1.40x | $-66.87 Million |
| 2021 | -52.98% | -269.03% | 0.14x | 1.44x | $-41.11 Million |
| 2022 | -45.36% | -257.39% | 0.12x | 1.43x | $-50.06 Million |
| 2023 | -165.99% | -448.89% | 0.15x | 2.50x | $-83.23 Million |
| 2024 | -168.74% | -931.65% | 0.06x | 2.98x | $-138.12 Million |
Industry Comparison
This section compares Liquidia Technologies Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $184,483,093
- Average return on equity (ROE) among peers: -41.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Liquidia Technologies Inc (LQDA) | $22.05 Million | 0.00% | 11.52x | $2.15 Billion |
| Aadi Bioscience Inc (AADI) | $136.41 Million | -80.71% | 0.16x | $17.03 Million |
| America Great Health (AAGH) | $-48.07K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $408.66 Million | -216.05% | 5.93x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $59.51 Million |
| ABIVAX Société Anonyme (AAVXF) | $48.18 Million | -23.29% | 0.12x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $740.10 Million |
| Abeona Therapeutics Inc (ABEO) | $102.55 Million | -82.14% | 0.47x | $210.89 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $117.44 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $316.52 Million |